Press & News

The next generation biopharmaceuticals

Press releases

2018-11-16

Interim Report – January to September 2018

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter 2018. Financial Highlights Revenue for the 3rd Quarter 2018 amounted to SEK 25.6...[read more]

Older press releases

2018-09-24

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that a major Nordic study (“Affibody-3”) will begin using Affibody’s PET imaging agent ABY-025.[read more]

2018-08-23

Interim Report – January to June 2018

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter 2018.[read more]

2018-05-21

Affibody Presents at Anglonordic Life Science

Solna, Sweden, May 21, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Anglonordic Life Science conference, a UK and Nordic life science...[read more]

Affibodys latest Press releases

2019-02-22

Affibody Announces Fully Guaranteed Rights Issue

Solna, Sweden, February 22, 2019. Affibody Medical AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q2 (August 23, 2018)

Investor information